Bergen, Norway 14.9.22 

Lifecare AS (Lifecare) has signed a Letter of Intent (LOI) with Innovationspark
Mainz GmbH & Co KG (IVP). On this basis Lifecare and IVP will initiate an
intensive joint development of a new Lifecare manufacturing location in Mainz
(Germany), with an optimized infrastructure for sensor-production. In addition
to production, Lifecare intends to integrate and co-locate the existing
development units Lifecare Laboratory and Lifecare NanoBioSensors at the same
location.  
 
IVP is developing the "Mainz Innovation Park", which is situated adjacent to the
University of Mainz and University of Applied Sciences. Lifecare and IVP will in
cooperation develop up to 900 sqm in "LAB1", a modern and multifunctional
building for highly specialized laboratories including service and production
areas, and office floors. Based on the initial planning and adjustments from
IVP, the building and the location have been assessed as adequately stable and
hence suitable for Scanning Electron Microscopes necessary for Lifecare's sensor
production.  
 
Lifecare and IVP will work together to optimize the space planning for
production, laboratory and office spaces over the next three months and IVP hope
to submit the building application and agree on a long- term leasing agreement
by end of 2022. The new property will be handed over to Lifecare in 2024.  
 
IVP is a joint venture between GL Kayser Immobilien and IGM, both located in
Mainz (Germany) and J. Molitor Immobilien GmbH in Ingelheim am Rhein (Germany).
The joint venture partners hold a high level of industry and project development
experience, as well as a distinctive know-how for real estate in the research
and pharmaceutical sector. J. Molitor Immobilien GmbH and subsidiaries have a
broad experience from development and successful realization of laboratory and
research facilities for various institutes of the University of Mainz, BioNTech
SE, Boehringer Ingelheim Pharma GmbH & Co.KG, Merck KGaA and other well-known
companies.  
 
  
Further information 
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40 
 
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Joacim Holter, CEO at Lifecare AS, on 14.9.2022 at
7:57 CET.